MDS with ring sideroblasts (RS), usually associated with SF3B1 mutations, typically present with anemia that can benefit from luspatercept, an activin receptor ligand trap inhibitor of the transforming growth factor (TGF)-β pathway (Fig. 2). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.